OKY 1581

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414558

CAS#: 75987-18-7

Description: OKY 1581 is a new thromboxane synthetase inhibitor


Chemical Structure

img
OKY 1581
CAS# 75987-18-7

Theoretical Analysis

MedKoo Cat#: 414558
Name: OKY 1581
CAS#: 75987-18-7
Chemical Formula: C16H14NNaO2
Exact Mass: 275.0922
Molecular Weight: 275.28
Elemental Analysis: C, 69.81; H, 5.13; N, 5.09; Na, 8.35; O, 11.62

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: OKY 1581; OKY1581; OKY-1581

IUPAC/Chemical Name: 2-Propenoic acid, 2-methyl-3-(4-(3-pyridinylmethyl)phenyl)-, sodium salt, (E)-

InChi Key: ZAPOSLLMEZKFQS-NBYYMMLRSA-M

InChi Code: InChI=1S/C16H15NO2.Na/c1-12(16(18)19)9-13-4-6-14(7-5-13)10-15-3-2-8-17-11-15;/h2-9,11H,10H2,1H3,(H,18,19);/q;+1/p-1/b12-9+;

SMILES Code: O=C([O-])/C(C)=C/C1=CC=C(CC2=CC=CN=C2)C=C1.[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 275.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Watanabe T, Utsugi M, Mitsukawa M, Suga T, Fujitani H. Hypolipidemic effect and enhancement of peroxisomal beta-oxidation in the liver of rats by sodium-(E)-3-(4-(3-pyridylmethyl)phenyl)-2-methyl propenoate (OKY-1581), a potent inhibitor of TxA2 synthetase. J Pharmacobiodyn. 1986 Dec;9(12):1023-31. doi: 10.1248/bpb1978.9.1023. PMID: 3572715.

2: Garcia-Szabo R, Kern DF, Malik AB. Pulmonary vascular response to thrombin: effects of thromboxane synthetase inhibition with OKY-046 and OKY-1581. Prostaglandins. 1984 Dec;28(6):851-66. doi: 10.1016/0090-6980(84)90039-x. PMID: 6543018.

3: Sasaki T, Wakai S, Asano T, Takakura K, Sano K. Prevention of cerebral vasospasm after SAH with a thromboxane synthetase inhibitor, OKY-1581. J Neurosurg. 1982 Jul;57(1):74-82. doi: 10.3171/jns.1982.57.1.0074. PMID: 7201009.

4: Casey LC, Fletcher JR, Zmudka MI, Ramwell PW. Prevention of endotoxin-induced pulmonary hypertension in primates by the use of a selective thromboxane synthetase inhibitor, OKY 1581. J Pharmacol Exp Ther. 1982 Aug;222(2):441-6. PMID: 6896528.

5: Tilden SJ, Underwood DC, Cowen KH, Wegmann MJ, Graybar GB, Hyman AL, McNamara DB, Kadowitz PJ. Effects of OKY 1581 on bronchoconstrictor responses to arachidonic acid and PGH2. J Appl Physiol (1985). 1987 May;62(5):2066-74. doi: 10.1152/jappl.1987.62.5.2066. PMID: 2954941.

6: Rosenblum WI, El-Sabban F. Effect of OKY-1581, a thromboxane synthesis inhibitor, on the platelet aggregation and vasodilation induced by injury of mouse pial arterioles. J Cereb Blood Flow Metab. 1983 Mar;3(1):122-6. doi: 10.1038/jcbfm.1983.15. PMID: 6681612.

7: Uotila P, Matintalo M, Dahl ML. Arachidonic acid induced platelet aggregation and thromboxane formation is inhibited by OKY-1581. Prostaglandins Leukot Med. 1983 Nov;12(3):299-303. doi: 10.1016/0262-1746(83)90008-2. PMID: 6419237.

8: Guarner F, Boughton-Smith NK, Blackwell GJ, Moncada S. Reduction by prostacyclin of acetaminophen-induced liver toxicity in the mouse. Hepatology. 1988 Mar-Apr;8(2):248-53. doi: 10.1002/hep.1840080210. PMID: 3281885.

9: Waring PH, Hyman AL, Nandiwada PA, Kadowitz PJ. Influence of OKY-1581 on responses to arachidonic acid in the feline pulmonary vascular bed. Prostaglandins Leukot Essent Fatty Acids. 1988 Mar;31(3):117-22. doi: 10.1016/0952-3278(88)90107-x. PMID: 3131783.

10: Shea MJ, Driscoll EM, Romson JL, Pitt B, Lucchesi BR. Effect of OKY-1581, a thromboxane synthetase inhibitor, on coronary thrombosis in the conscious dog. Eur J Pharmacol. 1984 Oct 15;105(3-4):285-91. doi: 10.1016/0014-2999(84)90620-4. PMID: 6542526.